ATLAS IDE Study Results

Treat anterior and posterior aneurysms with confidence

The ATLAS IDE studies have shown excellent results from the largest pivotal data to date with high complete occlusion and low complication rates using the Neuroform Atlas™ Stent System.

Atlas IDE Study

The Atlas anterior and posterior IDE studies are the largest of their kind to date, with 298 patients having diverse anatomical locations.

Anterior
Posterior
  Anterior
n=182
Posterior
n=116
Primary efficacy endpoint¹ 84.7% 76.7%
Primary safety endpoint² 4.4% 4.3%
Retreatment³ 3.8% 7.8%

1. Primary efficacy endpoint complete aneurysm occlusion (Raymond-Roy class 1) on 12-month angiography, in the absence of retreatment or parent artery stenosis (>50%) at the target location.
2. Primary safety endpoint of any major ipsilateral stroke or neurological death within 12 months.
3. Retreatment rate.

Atlas Posterior: Jankowitz BT, Jadhav AP, Gross B, et al, Pivotal trial of the Neuroform Atlas stent for treatment of posterior circulation aneurysms: one-year outcomes, Journal of NeuroInterventional Surgery 2022;14:143-148.
Atlas Anterior: Zaidat OO, Hanel RA, Sauvageau EA, et al. Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysm. Stroke. 2020; 51:2087 -2094.

"Atlas remains near and dear to my heart… It was designed to be simple to use and highly effective, with pinpoint accuracy and the lowest metal-to-artery ratio of any device on the US market."

Dr. Brian Jankowitz